Castle Biosciences (CSTL) Cash & Current Investments (2018 - 2026)

Castle Biosciences has disclosed Cash & Current Investments across 9 years of filings, most recently posting $261.7 million for Q1 2026.

• Cash & Current Investments for Q1 2026 came in at $261.7 million, down 4.89% year-over-year; the trailing twelve-month figure through Mar 2026 was $261.7 million (down 4.89% YoY), and the FY2025 annual result was $299.5 million, up 2.17% from the prior year.
• Cash & Current Investments came in at $261.7 million for Q1 2026 at Castle Biosciences, down from $299.5 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $309.0 million in Q1 2022 to a low of $225.5 million in Q2 2023.
• The 5-year median for Cash & Current Investments is $266.0 million (2022), against an average of $265.2 million.
• Across the five-year window, Cash & Current Investments declined 26.76% in 2022 and gained 21.8% in 2024, its largest moves.
• Castle Biosciences' Cash & Current Investments stood at $258.6 million in 2022, then fell by 6.0% to $243.1 million in 2023, then gained by 20.58% to $293.1 million in 2024, then increased by 2.17% to $299.5 million in 2025, then decreased by 12.62% to $261.7 million in 2026.
• The last three Cash & Current Investments figures came in at $261.7 million (Q1 2026), $299.5 million (Q4 2025), and $287.6 million (Q3 2025), per Business Quant data.